IVVD / Invivyd, Inc. - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

Invivyd Announces Proposed Public Offering of Common Stock

Exhibit 99.1 Invivyd Announces Proposed Public Offering of Common Stock WALTHAM, Mass., August 20, 2025 (GLOBE NEWSWIRE) - Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Invivyd intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the share

Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter’s Option to Purchase Additional Shares

Exhibit 99.3 Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter’s Option to Purchase Additional Shares WALTHAM, Mass., August 22, 2025 (GLOBE NEWSWIRE) – Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced the closing of its previously announced underwritten public offering of 89,234,480 shares of its common stock, which includes the exercise in full

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 20, 2025 Invivyd, Inc. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 20, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Invivyd, Inc. 74,811,404 Shares of Common Stock (par value $0.0001 per share) Pre-Funded Warrants to Purchase 21,342,442 Shares of Common Stock Underwriting Agreement

Exhibit 1.1 Invivyd, Inc. 74,811,404 Shares of Common Stock (par value $0.0001 per share) Pre-Funded Warrants to Purchase 21,342,442 Shares of Common Stock Underwriting Agreement August 20, 2025 Cantor Fitzgerald & Co. As Representative of the several Underwriters listed in Schedule A hereto c/o Cantor Fitzgerald & Co. 110 East 59th Street, 6th Floor New York, NY 10022 Ladies and Gentlemen: Invivy

Security Type

Calculation of Filing Fee Tables S-3 Invivyd, Inc. Table 1: Newly Registered and Carry Forward Securities ☑Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effec

Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants

Exhibit 99.2 Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants WALTHAM, Mass., August 20, 2025 (GLOBE NEWSWIRE) – Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced the pricing of an underwritten public offering of 74,811,404 shares of its common stock at an offering price of $0.52 per share and, to certain investors, in lieu of common stock, pre-

74,811,404 Shares of Common Stock Pre-Funded Warrants to Purchase up to 21,342,442 Shares of Common Stock

424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-267643 PROSPECTUS SUPPLEMENT  (To Prospectus dated October 5, 2022) 74,811,404 Shares of Common Stock Pre-Funded Warrants to Purchase up to 21,342,442 Shares of Common Stock We are offering 74,811,404 shares of our common stock, par value $0.0001 per share, and, in lieu of common stock to certain investors that so choose, pre-funded warra

FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK

Exhibit 4.1 Final Form FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [●] (subject to adjustment) Warrant No. [●] Original Issue Date: [●], 2025 Invivyd, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [●] or its registered assigns (the “Holder”), is entitl

Common Stock Pre-Funded Warrants to Purchase Shares of Common Stock

FWP Issuer Free Writing Prospectus dated August 20, 2025 Filed Pursuant to Rule 433 of the Securities Act of 1933 Registration Statement No.

SUBJECT TO COMPLETION, DATED AUGUST 20, 2025

424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-267643 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to

LIMITED POWER OF ATTORNEY FOR SECTION 16 AND RULE 144 REPORTING OBLIGATIONS

Exhibit 24.1 LIMITED POWER OF ATTORNEY FOR SECTION 16 AND RULE 144 REPORTING OBLIGATIONS Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Jill Andersen, Katherine Fisher, Kiernan Decker, Stephen Nicolai, Steve Abrams and Amanda Brown, signing singly and each acting individually, as the undersigned’s true and lawful attorney‑in‑fact with full power and

LIMITED POWER OF ATTORNEY FOR SECTION 16 AND RULE 144 REPORTING OBLIGATIONS

Exhibit 24.1 LIMITED POWER OF ATTORNEY FOR SECTION 16 AND RULE 144 REPORTING OBLIGATIONS Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of William E. Duke, Jill Andersen, Katherine Fisher, Kiernan Decker, Stephen Nicolai, Steve Abrams and Amanda Brown, signing singly and each acting individually, as the undersigned’s true and lawful attorney‑in‑fact wi

LIMITED POWER OF ATTORNEY FOR SECTION 16 AND RULE 144 REPORTING OBLIGATIONS

Exhibit 24.1 LIMITED POWER OF ATTORNEY FOR SECTION 16 AND RULE 144 REPORTING OBLIGATIONS Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of William E. Duke, Jill Andersen, Katherine Fisher, Kiernan Decker, Stephen Nicolai, Steve Abrams and Amanda Brown, signing singly and each acting individually, as the undersigned’s true and lawful attorney‑in‑fact wi

LIMITED POWER OF ATTORNEY FOR SECTION 16 AND RULE 144 REPORTING OBLIGATIONS

Exhibit 24.1 LIMITED POWER OF ATTORNEY FOR SECTION 16 AND RULE 144 REPORTING OBLIGATIONS Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of William E. Duke, Jill Andersen, Katherine Fisher, Kiernan Decker, Stephen Nicolai, Steve Abrams and Amanda Brown, signing singly and each acting individually, as the undersigned’s true and lawful attorney‑in‑fact wi

LIMITED POWER OF ATTORNEY FOR SECTION 16 AND RULE 144 REPORTING OBLIGATIONS Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of William E. Duke, Katherine Fisher, Kiernan Decker, Stephen Nicolai, Steve Abra

Exhibit 24.1 LIMITED POWER OF ATTORNEY FOR SECTION 16 AND RULE 144 REPORTING OBLIGATIONS Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of William E. Duke, Katherine Fisher, Kiernan Decker, Stephen Nicolai, Steve Abrams and Amanda Brown, signing singly and each acting individually, as the undersigned’s true and lawful attorney‑in‑fact with full power a

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of his

EX-99.3 Exhibit 99.3 Corporate Deck August 2025 © 2025 Invivyd, Inc. Invivyd®, the Invivyd logo, Pemgarda® and the Ribbon logo are registered trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners. 1 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40703 INVIVYD, I

Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19

EX-99.2 Exhibit 99.2 Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19 • Alignment follows Type C meeting for VYD2311 as previously disclosed • BLA pathway for VYD2311 to be supported by a single, Phase 2/3 randomized, double-blind, placebo-controlled trial with a primary

INVIVYD, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share amounts) June 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 34,905 $ 69,349 Accounts receivable, net 8,698 10,906 Prepaid ex

EX-99.1 Exhibit 99.1 Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights • PEMGARDA® (pemivibart) net product revenue of $11.8 million reported for Q2 2025, representing 413% growth year-over-year • Invivyd’s target of near-term profitability (1H 2025) was not met but remains possible with the upcoming respiratory virus season • Announced alignment with U.S. FDA on

Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Invivyd and Leading Researchers Form SPEAR (

Exhibit 99.1 Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome - SPEAR Study Group initiated following multiple, independent reports of substantial clinical benefit associated with PEMGARDA® (pemivibart) therapy among people with Long COVID - SPEA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 2, 2025 Invivyd, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 2, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 26, 2025 Invivyd, Inc. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 26, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number

EX-99.1

Exhibit 99.1 Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection • Attractive safety profile demonstrated across all dosing cohorts and routes of administration (IV, SC, and IM); all reported adverse events (AEs) deemed unrelated or classified as mil

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 20, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number)

INVIVYD, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share amounts) March 31, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 48,078 $ 69,349 Accounts receivable 8,561 10,906 Prepaid expens

Exhibit 99.1 Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights • PEMGARDA™ (pemivibart) net product revenue of $11.3 million reported for Q1 2025, influenced by planned transition (Jan/Feb) from a contracted to an internalized sales force • PEMGARDA revenue re-acceleration observed in Q2 2025 to date • Invivyd continues to target near-term profitability (1H 2025)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40703 INVIVYD,

u Executive Summary u Commercial Update u R&D Overview u Clinical & Regulatory Finance Q&A 3

Exhibit 99.2 INVIVYD Q1 2025 FINANCIAL RESULTS & BUSINESS HIGHLIGHTS May 15, 2025 © 2025 Invivyd, Inc. Invivyd , Pemgarda , and the Ribbon logos are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Priv

Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 15, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number)

EX-99.1

Exhibit 99.1 Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles • Multiple HCPs have requested from Invivyd a monoclonal antibody (mAb) for treatment of active measles infection and post-exposure prophylaxis to reduce the consequence of outbreaks. Such a medicine could accelerate the pathway to functional eradication of measles • Measles (rubeola)

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 12, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 21, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 18, 2025 Invivyd, Inc. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 18, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Loan and Security Agreement, dated April 18, 2025, between Invivyd, Inc. and Silicon Valley Bank, a Division of First-Citizens Bank & Trust Company

Exhibit 10.1 Certain Confidential Information in this document, marked by “[***]”, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) is dated as of the Effective Date between SILICON VALLEY BANK, A DIVISION OF FIRST-CITIZENS BANK & TRUST COM

EX-99.1

Exhibit 99.1 Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) – Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it has signed a $30 million term loan facility with Silicon Valley Bank (SVB), a division of First Citizens Ba

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

Exhibit 99.1 Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors WALTHAM, Mass., March 26, 2025 (GLOBE NEWSWIRE) - Invivyd, Inc. (Nasdaq: IVVD) is pleased to announce the appointment of Ajay Royan to its Board of Directors. Mr. Royan is a venture capitalist focused on transformational companies that have solved critical problems in healthcare, technology, and energy.

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 22, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Employment Agreement by and between the Registrant and Timothy Lee, dated May 30, 2024.

Exhibit 10.16 Employment AGREEMENT This Employment Agreement (“Agreement”) is made between Invivyd, Inc., a Delaware corporation (the “Company”), and Timothy Lee (“Executive”), this 30th day of May, 2024. Whereas, the Company desires to employ Executive in the role of Chief Commercial Officer of the Company, providing Executive with certain compensation and benefits in return for such employment s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 20, 2025 Invivyd, Inc. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 20, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40703 INVIVYD, INC. (

Form of Indemnification Agreement with Executive Officers and Directors.

Exhibit 10.4 INVIVYD, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is dated as of , 20, and is between Invivyd, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). RECITALS A. Indemnitee’s service to the Company substantially benefits the Company. B. Individuals are reluctant to serve as directors or officers of corporations or in certain other cap

First Amendment to the Employment Agreement of Julie Green, by and between the Registrant and Julie Green, dated October 23, 2024.

Exhibit 10.15 FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT OF JULIE GREEN This First Amendment to the Employment Agreement of Julie Green (the “Amendment”) is entered into this October 23, 2024 (the “Amendment Effective Date”), by and between JULIE GREEN (the “Executive”) and Invivyd, Inc. (the “Company”). Recitals WHEREAS, the Company and Executive have entered into that certain Employment Agreeme

INVIVYD, INC. Condensed Consolidated Balance Sheets (In thousands, except share and per share amounts)

Exhibit 99.1 Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights • Achieved Q4 2024 PEMGARDA™ (pemivibart) net product revenue of $13.8 million, representing 48% growth over Q3 2024 net product revenue of $9.3 million; full-year 2024 net product revenue totaled $25.4 million • 2024 year-end cash and cash equivalents of $69.3 million • Continu

Insider Trading Prevention Policy of the Registrant.

Exhibit 19.1 InSIDER TRADING PREVENTION Policy 1.0 POLICY It is the policy of Invivyd, Inc. and its subsidiaries (“Invivyd”) to prohibit insider trading, i.e., the purchase or sale of a company’s securities by anyone who is aware of Material Non-Public Information (as defined below) about that company. Taking advantage of this privileged information is considered a breach of the individual’s fiduc

2021 Equity Incentive Plan, as amended, and Forms of Stock Option Grant Notice, Stock Option Agreement, Exercise Notice, RSU Award Grant Notice and RSU Award Agreement.

Exhibit 10.2 INVIVYD, INC. 2021 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JULY 27, 2021 APPROVED BY THE STOCKHOLDERS: JULY 29, 2021 1. GENERAL. (a) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; (ii) the Prior Plan’s Available Reserve

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

Exhibit 99.1 Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1 • New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA™ (pemivibart) against LP.8.1 • Centers for Disease Control reports LP.8.1, XEC and KP.3.1.1 together constitute the majority of current national SARS-CoV-2 varian

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 5, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number

FDA Declined Invivyd’s Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Exis

Exhibit 99.1 FDA Declined Invivyd’s Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients • FDA’s reasoning appears to center on a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 21, 2025 Invivyd, Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 21, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 3, 2025 Invivyd, Inc. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 3, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Num

Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population

Exhibit 99.2 Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population • Recruitment completed and all doses administered for VYD2311 ongoing Phase 1/2 clinical trial (40 subjects) evaluating 3 routes of administration • Phase 1/2 clinical data for VYD2311 to date are positive for bot

Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability

Exhibit 99.1 Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability • Preliminary Q4 2024 PEMGARDA™ (pemivibart) net product revenue of $13.8 million, 48% growth over Q3 2024 net product revenue of $9.3 million • Preliminary Q4 2024 total operating costs and expenses of approximately $32 million, 55% reduction comp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 27, 2025 Invivyd, Inc. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 27, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Num

Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Pa

Exhibit 99.1 Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients • Treatment immunobridging analysis, routinely updated for contemporary SARS-CoV-2 variants, compares pemivibart antiviral titers

invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

Exhibit 99.1 invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC • New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA™ (pemivibart) against XEC • Centers for Disease Control reports XEC and KP.3.1.1 (previously disclosed as susceptible to PEMGARDA) together constitute the majority of national

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2025 Invivyd, Inc. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 27, 2024 Invivyd, Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 27, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Nu

IVVD / Invivyd, Inc. / Polaris Venture Partners V, L.P. - SC 13D/A Activist Investment

SC 13D/A 1 d896430dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4) INVIVYD, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 00534A102 (CUSIP Number) Lauren Crockett Polaris Partners One Marina Park Drive, 8th Floor Boston, MA 02210 (781) 290-0770 (Na

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 27, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Nu

IVVD / Invivyd, Inc. / MAVERICK CAPITAL LTD - SC 13G/A Passive Investment

SC 13G/A 1 d848877dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Invivyd, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00534A102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the

u Executive Summary u CANOPY Phase 3 Clinical Trial: 12 Month Data Update u Pipeline u Commercial Update Finance Q&A 3

Exhibit 99.2 INVIVYD Q3 2024 FINANCIAL RESULTS & BUSINESS HIGHLIGHTS November 14, 2024 © 2024 Invivyd, Inc. Invivyd , Pemgarda , and the Ribbon logos are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S.

Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 14, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40703 INVIV

Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Exhibit 99.1 Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights • Q3 2024 PEMGARDA™ (pemivibart) net product revenue of $9.3 million; Invivyd ended Q3 2024 with $106.9 million in cash and cash equivalents • Targets near-term (1H 2025) profitability with existing cash and cash equivalents, anticipated growth of net product revenue, and various operational efficiency

IVVD / Invivyd, Inc. / Deep Track Capital, LP Passive Investment

SC 13G/A 1 deeptrack-ivvd093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* INVIVYD, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 00534A102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the ap

Invivyd Announces

Exhibit 99.3 Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor • The New England Journal of Medicine (NEJM) Letter to the Editor outlines the novel, rapid immunobridging authorization pathway for PEMGARDA and provide

IVVD / Invivyd, Inc. / GV 2019, L.P. - SC 13G/A Passive Investment

SC 13G/A 1 tm2426694d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Invivyd, Inc. (f/k/a Adagio Therapeutics, Inc.) (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00534A102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 29, 2024 Invivyd, Inc. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 29, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Num

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants

Exhibit 99.2 Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants • Following strong protection (84% relative risk reduction versus placebo) demonstrated through month 6 with pemivibart, CANOPY clinical

Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability

Exhibit 99.1 Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability • Preliminary Q3 2024 PEMGARDA™ (pemivibart) net product revenue of $9.3 million; Invivyd ended Q3 2024 with approximately $107 million in cash and cash equivalents • Expects to finish 2024 with $65 million or more in cash and cash equivalents • Withdraws for

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 23, 2024 Invivyd, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 23, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File N

Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)

Exhibit 99.1 Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart) • Independent evaluation of KP.3.1.1 and LB.1 variants shows in vitro pseudovirus neutralization potency of PEMGARDA in-line with prior variants tested • Proprietary, ongoing SARS-CoV-2 spike analyses demonstrate consistent str

Corporate Overview September 2024 © 2024 Invivyd, Inc. Invivy , Pemgar , and the Ribbon logos are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners.

EX-99.1 Exhibit 99.1 Corporate Overview September 2024 © 2024 Invivyd, Inc. Invivy , Pemgar , and the Ribbon logos are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Refo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 6, 2024 Invivyd, Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 6, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA

Exhibit 99.1 Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™ WALTHAM, Mass., September 4, 2024 – Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced dosing of the first participants i

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 4, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 3, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest

Exhibit 99.1 Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest • New pseudovirus in vitro neutralization data show continued neutralizing activity of PEMGARDATM (pemivibart) against KP.3.1.1, LB.1, and other SARS-CoV-2 variants tested • Center for Disease Control reports KP.3.1.1 is the

Invivyd Announces PEMGARDA

Exhibit 99.1 Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial • In all-comer cohort of immunocompetent individuals at risk of contracting symptomatic COVID-19 in their everyday social interactions, participants receiving pemivibart experienced a 1.9% ra

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of his

Exhibit 99.2 INVIVYD CANOPY DATA UPDATE August 27, 2024 © 2024 Invivyd, Inc. Invivyd , Pemgarda , and the Ribbon logos are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 27, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Separation Agreement by and between the Company and David Hering, dated May 3, 2024.

Exhibit 10.3 SEPARATION AGREEMENT April 19, 2024, as modified on May 3, 2024 David Hering [***] [***] Re: Separation Agreement Dear Dave: This letter sets forth the substance of the separation agreement (the “Agreement”) which Invivyd, Inc. (the “Company”) is offering to you to aid in your employment transition. 1. Separation. Your employment is ending pursuant to Section 3(d) of your Employment A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40703 INVIVYD, I

Separation Agreement by and between the Company and Jeremy Gowler, dated May 31, 2024.

Exhibit 10.4 SEPARATION AGREEMENT May 31, 2024 Jeremy Gowler [***] [***] Re: Separation Agreement Dear Jeremy: This letter sets forth the substance of the separation agreement (the “Agreement”) which Invivyd, Inc. (the “Company”) is offering to you to aid in your employment transition. 1. Separation. Your last day of work with the Company and your employment termination date will be June 29, 2024

INVIVYD, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share amounts) June 30, 2024 December 31, 2023 Assets Current assets: Cash and cash equivalents $ 147,881 $ 200,641 Accounts receivable, net 2,888 —  Inventory, n

Exhibit 99.1 INVIVYD REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS • PEMGARDA™ launched commercially in Q2 2024 with $2.3 million of net product revenue • Notable acceleration of commercial results in early Q3 2024, with the anticipated peak fall/winter respiratory virus season approaching • New commercial leadership with Chief Commercial Officer, Tim Lee, an experie

Employment Agreement by and between the Company and Timothy Lee, dated May 30, 2024.

Exhibit 10.1 Employment AGREEMENT This Employment Agreement (“Agreement”) is made between Invivyd, Inc., a Delaware corporation (the “Company”), and Timothy Lee (“Executive”), this 30th day of May, 2024. Whereas, the Company desires to employ Executive in the role of Chief Commercial Officer of the Company, providing Executive with certain compensation and benefits in return for such employment se

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of his

Exhibit 99.2 INVIVYD Q2 2024 FINANCIAL RESULTS & BUSINESS HIGHLIGHTS August 14, 2024 © 2024 Invivyd, Inc. Invivyd , Pemgarda , and the Ribbon logos are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. P

Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants

Exhibit 99.1 Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants • Pseudovirus in vitro neutralization data show continued neutralizing activity of VYD222 (pemivibart) against the KP.1.1 FLiRT and KP.3 SARS-CoV-2 variants, virus selections representative of current dominant strains and the most recent FLiRT-containing viruses • Invivyd’s new

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 14, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number

Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer

Exhibit 99.1 Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer • Mr. Lee joins Invivyd with a history of high-quality commercial execution at Alexion, Biohaven and Amylyx • Appointment intended to accelerate the addition of commercial capabilities associated with orphan medicines to the ongoing PEMGARDA™ commercial launch • William Duke, Jr., Chief Financial Officer, app

Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for S

Exhibit 99.2 Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies • Newly outlined pathway provides a practical, expedient, repeatable immunobridging approach to potential eme

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 30, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 21, 2024 Invivyd, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 21, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Invivyd Elects Two New Independent Members to its Board of Directors

Exhibit 99.1 Invivyd Elects Two New Independent Members to its Board of Directors WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) – Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that two new independent directors, Dr. Srishti Gupta and Kevin F. McLaughlin, were elected to its Board of Directors at th

Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights

Exhibit 99.1 Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights • Launched PEMGARDA™ in the U.S. for COVID-19 pre-exposure prophylaxis (PrEP) in certain adults and adolescents with moderate-to-severe immune compromise • Reported interim exploratory COVID-19 clinical event data from CANOPY Phase 3 clinical trial of VYD222 • Received product-specific reimbursement co

Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number)

As filed with the Securities and Exchange Commission on May 9, 2024

As filed with the Securities and Exchange Commission on May 9, 2024 Registration No.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of his

Exhibit 99.2 INVIVYD Q1 2024 FINANCIAL RESULTS & BUSINESS HIGHLIGHTS May 9, 2024 © 2024 Invivyd, Inc. Invivyd , Pemgarda , and the Ribbon logos are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Priva

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40703 INVIVYD, INC.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(3) Proposed Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee Equity Common Stock, $0.00

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 7, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback

Exhibit 99.1 Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback • Pathway leverages immunobridging approach via serum virus neutralizing antibody (sVNA) titers enabled by prior successful COVID-19 treatment clinical trial “STAMP” conducted with prototype antibody adintrevimab • Com

INVIVYD, INC. 1601 Trapelo Road, Suite 178 Waltham, MA 02451

INVIVYD, INC. 1601 Trapelo Road, Suite 178 Waltham, MA 02451 April 18, 2024 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Lauren Hamill Re: Invivyd, Inc. Registration Statement on Form S-3 Filed February 9, 2024 File No. 333-276986 Request for Acceleration of Effective Date To Whom It May Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 11, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Invivyd Announces CEO Transition Jeremy Gowler appointed Interim CEO

Exhibit 99.1 Invivyd Announces CEO Transition Jeremy Gowler appointed Interim CEO WALTHAM, Mass., April 12, 2024 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that the company’s Board of Directors has appointed Jeremy Gowler as Interim Chief Executive Officer (CEO), effecti

First Amendment to the Employment Agreement of Jeremy Gowler, by and between the Registrant and Jeremy Gowler, dated April 11, 2024 (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K (File No. 001-40703), filed with the Securities and Exchange Commission on April 12, 2024).

Exhibit 10.1 FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT OF JEREMY GOWLER This FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT OF JEREMY GOWLER (the “Amendment”) is entered into this April 11, 2024 (the “Amendment Effective Date”), by and between JEREMY GOWLER (the “Executive”) and INVIVYD, INC. (the “Company”). RECITALS WHEREAS, the Company and Executive have entered into that certain Employment Agre

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of his

Exhibit 99.2 PEMGARDA LAUNCH UPDATE April 4, 2024 © 2024 Invivyd, Inc. Invivyd , Pemgarda , and the Ribbon logos are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform

Invivyd Provides PEMGARDATM Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million

Exhibit 99.1 Invivyd Provides PEMGARDATM Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million • PEMGARDA now commercially available in the U.S. for pre-exposure prophylaxis (PrEP) of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise • Based on anticipated net product revenue and continued optimization of opera

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 4, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number

Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights

Exhibit 99.1 Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights • Received emergency use authorization for PEMGARDA™, a monoclonal antibody (mAb) authorized in the U.S. for pre-exposure prophylaxis (PrEP) of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise • PEMGARDA product availability in the U.S. anticipated imminently • PEMGARDA

Incentive Compensation Recovery Policy of the Registrant.

Exhibit 97.1 Incentive Compensation Recovery Policy 1.0 INTRODUCTION 1.1 Invivyd, Inc. (the “Company”) is committed to conducting business in accordance with the highest ethical and legal standards, and the Board of Directors of the Company (the “Board”) believes that a culture that emphasizes integrity and accountability is in the best interests of the Company and its stockholders and essential t

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 28, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Employment Agreement by and between the Registrant and Stacy Price, dated February 3, 2023.

Exhibit 10.11 Employment AGREEMENT This Employment Agreement (“Agreement”) is made between Invivyd, Inc., a Delaware corporation (the “Company”), and Stacy Price (“Executive”), this 3rd day of February, 2023. Whereas, the Company desires for Executive to provide services to the Company, and wishes to provide Executive with certain compensation and benefits in return for such employment services, a

Description of the Registrant’s Common Stock.

Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of the Annual Report on Form 10-K of which this exhibit forms a part, the only class of securities of Invivyd, Inc. (the “Company”) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is the Company’s common

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40703 INVIVYD, INC. (

Employment Agreement by and between the Registrant and Peter Schmidt, dated November 9, 2020.

Exhibit 10.9 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between Adagio Therapeutics, Inc., a Delaware corporation (the “Company”), and Peter Schmidt (the “Executive”) and is effective as of November 9, 2020 (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all r

Employment Agreement by and between the Registrant and Julie Green, dated January 24, 2024.

Exhibit 10.14 Employment AGREEMENT This Employment Agreement (“Agreement”) is made between Invivyd, Inc., a Delaware corporation (the “Company”), and Julie Green (“Executive”), this 24th day of January, 2024. Whereas, the Company and the Executive have entered into that certain Offer Letter dated April 14, 2022 (the “Offer Letter”), pursuant to which Executive has provided services to the Company

Employment Agreement by and between the Registrant and Robert Allen, dated March 14, 2023.

Exhibit 10.12 Employment AGREEMENT This Employment Agreement (“Agreement”) is made between Invivyd, Inc., a Delaware corporation (the “Company”), and Robert Allen (“Executive”), this 14th day of March, 2023. Whereas, the Company desires for Executive to provide services to the Company, and wishes to provide Executive with certain compensation and benefits in return for such employment services, an

First Amendment to the Employment Agreement of Peter Schmidt by and between the Registrant and Peter Schmidt, dated December 6, 2022.

Exhibit 10.10 FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT OF PETER SCHMIDT This First Amendment to the Employment Agreement of Peter Schmidt (the “Amendment”) is entered into this 6th day of December 2022 (the “Amendment Effective Date”), by and between Peter Schmidt (the “Executive”) and Invivyd, Inc. (the “Company”). Recitals WHEREAS, the Company and the Executive have entered into that certain

Form of Indemnification Agreement with Executive Officers and Directors.

Exhibit 10.4 INVIVYD, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is dated as of , 20, and is between Invivyd, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). RECITALS A. Indemnitee’s service to the Company substantially benefits the Company. B. Individuals are reluctant to serve as directors or officers of corporations or in certain other cap

Amendment No. 2 to the Cell Line License Agreement by and between the Registrant and WuXi Biologics (Hong Kong) Limited, dated March 13, 2024.

Exhibit 10.23 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***]”, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. CONFIDENTIAL AMENDMENT NO. 2 TO THE CELL LINE LICENSE AGREEMENT THIS AMENDMENT NO. 2 TO THE CELL LINE LICENSE AGREEMENT (this “Amendment No. 2”), effective as of March 13, 2024

2021 Equity Incentive Plan and Forms of Stock Option Grant Notice, Stock Option Agreement, Exercise Notice, RSU Award Grant Notice and RSU Award Agreement.

Exhibit 10.2 INVIVYD, INC. 2021 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JULY 27, 2021 APPROVED BY THE STOCKHOLDERS: JULY 29, 2021 1. GENERAL. (a) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; (ii) the Prior Plan’s Available Reserve

Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

Exhibit 99.1 Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19 • PEMGARDA (pemivibart) is authorized in the U.S. for PrEP of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise • Emergency use authorization based on positive immunobridging data and on safety data from the CANOPY clin

Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial

Exhibit 99.2 Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial • Analysis of secondary endpoint of symptomatic COVID-19 events in CANOPY is unrelated to regulatory filing or review, but may be hypothesis generating for future Invivyd discovery and development work • Today’s update on Day 67 and Day 90 event rates is the first of two planned public updates on s

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of his

Exhibit 99.3 PEMGARDA FDA EMERGENCY USE AUTHORIZATION March 22, 2024 © 2024 Invivyd, Inc. Invivyd , Pemgarda , and the Ribbon logos are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securitie

Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 22, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

ADGI / Adagio Therapeutics Inc / MAVERICK CAPITAL LTD - SC 13G Passive Investment

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Invivyd, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00534A102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru

JOINT FILING AGREEMENT

EX-99.A 2 d784351dex99a.htm EX-99.A EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the Ordinary Shares of Invivyd, Inc., dated as of February 14, 2024, is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the

Power of Attorney

EX-99.B 3 d784351dex99b.htm EX-99.B EXHIBIT B Power of Attorney KNOW ALL MEN BY THESE PRESENTS, that I, Lee S. Ainslie III, hereby make, constitute and appoint Trevor Wiessmann as my agent and attorney-in-fact for the purpose of executing (i) in my personal capacity or (ii) in my capacity as manager or other officer or representative of Maverick Capital Management, LLC, Maverick Capital, Ltd. or a

ADGI / Adagio Therapeutics Inc / Deep Track Capital, LP Passive Investment

SC 13G 1 deeptrack-ivvd020224.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* INVIVYD, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 00534A102 (CUSIP Number) February 2, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate

Filing Fee Table (filed herewith).

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities  Security Type   Security Class Title  Fee Calculation or  Carry Forward Rule Amount Registered (1)  Proposed Maximum Offering Price Per Unit   Maximum Aggregate  Offering Price  Fee Rate  Amount of  Registrati

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

Exhibit 99.1 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm (PCAOB ID 238) F-2 Consolidated Balance Sheets F-3 Consolidated Statements of Operations and Comprehensive Loss F-4 Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) F-5 Consolidated Statements of Cash Flows F-7 Notes to Consolidated Financial

As filed with the Securities and Exchange Commission on February 9, 2024

Table of Contents As filed with the Securities and Exchange Commission on February 9, 2024 Registration No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 5, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Num

ADGI / Adagio Therapeutics Inc / Adimab, LLC - SC 13D/A Activist Investment

SC 13D/A 1 d615807dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Invivyd, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 00534A102 (CUSIP Number) Philip Chase 7 Lucent Drive Lebanon, NH 03766 (603) 643-7110 (Name, Address and Teleph

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of his

Exhibit 99.1 CORPORATE OVERVIEW January 8, 2024 © 2024 Invivyd, Inc. Invivyd and the Invivyd logo are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 8, 2024 Invivyd, Inc. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 8, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents

Exhibit 99.1 Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents • EUA submission is based on positive initial results from the ongoing CANOPY Phase 3 pivotal clinical trial and ongoing in vitro neutralization activity against relevant SARS-CoV-2 variants • VYD222 demonstrates c

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 3, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 22, 2023 Invivyd, Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 22, 2023 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Controlled Equity OfferingSM Sales Agreement by and between the Registrant and Cantor Fitzgerald & Co., dated December 22, 2023 (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K (File No. 001-40703), filed with the Securities and Exchange Commission on December 22, 2023).

EX-10.1 Exhibit 10.1 Execution Version Invivyd, Inc. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement December 22, 2023 Cantor Fitzgerald & Co. 110 East 59th Street New York, NY 10022 Ladies and Gentlemen: Invivyd, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as f

EX-FILING FEES

Exhibit 107 The prospectus supplement to which this exhibit is attached is a final prospectus for the related offering. The maximum aggregate offering price of such offering is $75,000,000.

Up to $75,000,000 Common Stock

424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-267643 PROSPECTUS SUPPLEMENT (To Prospectus dated October 5, 2022) Up to $75,000,000 Common Stock We have entered into a Controlled Equity OfferingSM Sales Agreement, or the Sales Agreement, with Cantor Fitzgerald & Co., or Cantor, relating to shares of our common stock, par value $0.0001 per share, offered by this prosp

Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19

Exhibit 99.1 Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19 • VYD222 produced high serum virus neutralizing antibody titer levels in immunocompromised participants • Data supportive of an immunobridging approach to the EVADE study of adintrevimab • Overall favorable safety and tolerability profile of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 18, 2023 Invivyd, Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 18, 2023 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Nu

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of his

Exhibit 99.2 INVIVYD Q3 2023 FINANCIAL RESULTS & BUSINESS HIGHLIGHTS November 9, 2023 © 2023 Invivyd, Inc. Invivyd and the Invivyd logo are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Secur

Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Exhibit 99.1 Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights • Enrollment completed in CANOPY Phase 3 pivotal clinical trial investigating VYD222 for the prevention of symptomatic COVID-19 • Company expects to have initial CANOPY primary endpoint data by late 2023 or early Q1 2024 • Company aims to submit an application for Emergency Use Authorization (EUA) in t

Second Amended and Restated Commercial Manufacturing Services Agreement by and between the Registrant and WuXi Biologics (Hong Kong) Limited, dated September 19, 2023 (incorporated by reference to Exhibit 10.3 of the Registrant’s Quarterly Report on Form 10-Q (File No. 001-40703), filed with the Securities and Exchange Commission on November 9, 2023).

Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***]”, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SECOND AMENDED AND RESTATED COMMERCIAL MANUFACTURING SERVICES AGREEMENT SECOND AMENDED AND RESTATED COMMERCIAL MANUFACTURING SERVICES AGREEMENT THIS SECOND AMENDED AND RESTATED C

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2023 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40703 INVIVYD, INC.

Amendment Number Two to the Collaboration Agreement by and between the Registrant and Adimab, LLC, dated September 19, 2023 (incorporated by reference to Exhibit 10.2 of the Registrant’s Quarterly Report on Form 10-Q (File No. 001-40703), filed with the Securities and Exchange Commission on November 9, 2023).

Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***]”, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. FINAL [***] AMENDMENT NUMBER TWO TO THE COLLABORATION AGREEMENT This Amendment Number Two (this “Amendment”), dated September 19, 2023 (the “Amendment Two Effective Date”), amend

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of his

Exhibit 99.1 CORPORATE OVERVIEW September 2023 © 2023 Invivyd, Inc. Invivyd and the Invivyd logo are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. St

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 11, 2023 Invivyd, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 11, 2023 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File N

INVIVYD APPOINTS WILLIAM DUKE AS CHIEF FINANCIAL OFFICER

EX-99.1 Exhibit 99.1 INVIVYD APPOINTS WILLIAM DUKE AS CHIEF FINANCIAL OFFICER WALTHAM, Mass., September 5, 2023 (GLOBE NEWSWIRE) – Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced the appointment of William Duke as Chief Financial Officer. Mr. Duke will lead Invivyd’s financial st

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 5, 2023 Invivyd, Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 5, 2023 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Employment Agreement by and between the Registrant and William Duke, Jr. dated July 19, 2023 (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K (File No. 001-40703), filed with the Securities and Exchange Commission on September 5, 2023).

Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between Invivyd, Inc., a Delaware corporation (the “Company”), and William Duke (“Executive”), this 19th day of July, 2023. WHEREAS, the Company desires for Executive to provide services to the Company, and wishes to provide Executive with certain compensation and benefits in return for such employment services, and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR/ 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40703 INVIVYD, INC.

Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights

EX-99.1 Exhibit 99.1 Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights • Reported positive initial Phase 1 VYD222 clinical trial data, including favorable safety data and robust serum neutralizing titers from all three dose levels tested • Plans to pursue rapid initiation of a 750-participant pivotal clinical trial of VYD222 (CANOPY) that will utilize Day 28 serum neutr

First Amendment to the Employment Agreement of David Hering by and between the Registrant and David Hering, dated June 15, 2023 (incorporated by reference to Exhibit 10.1 of the Registrant’s Quarterly Report on Form 10-Q (File No. 001-40703), filed with the Securities and Exchange Commission on August 10, 2023).

Exhibit 10.1 FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT OF DAVID HERING This First Amendment to the Employment Agreement of David Hering (the “First Amendment”) is entered into this June 15, 2023 (the “Effective Date”), by and between David Hering (the “Executive”) and Invivyd, Inc. (the “Company”). Recitals WHEREAS, the Company and the Executive have entered into that certain Employment Agreemen

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 10, 2023 Invivyd, Inc. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 10, 2023 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Numb

INVIVYD ANNOUNCES APPOINTMENT OF SARA COTTER TO BOARD OF DIRECTORS

Exhibit 99.1 INVIVYD ANNOUNCES APPOINTMENT OF SARA COTTER TO BOARD OF DIRECTORS WALTHAM, Mass., JULY 27, 2023 — Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced the appointment of Sara Cotter to its board of directors. Ms. Cotter brings extensive leadership experience spanning hea

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 25, 2023 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 29, 2023 Invivyd, Inc. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 29, 2023 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of his

EX-99.1 Exhibit 99.1 Corporate Overview June 2023 © 2023 Invivyd, Inc. Invivyd and the Invivyd logo are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995.

Amendment No. 1 to the Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 of the Company’s Current Report on Form 8-K (File No. 001-40703), filed with the Securities and Exchange Commission on May 25, 2023).

Exhibit 3.2 AMENDMENT NO. 1 TO THE AMENDED AND RESTATED BYLAWS OF INVIVYD, INC. (A DELAWARE CORPORATION) The Amended and Restated Bylaws (the “Bylaws”) of Invivyd, Inc., a Delaware corporation, are hereby amended as follows, effective as of May 23rd, 2023. 1. Section 5(d) of Article III of the Bylaws is hereby amended and restated in its entirety to read as follows: “Notwithstanding anything in Se

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 23, 2023 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Certificate of Amendment to the Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K (File No. 001-40703), filed with the Securities and Exchange Commission on May 25, 2023).

Exhibit 3.1 STATE OF DELAWARE CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INVIVYD, INC. Invivyd, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: FIRST: Article V, Section B, Subsections 2 and 3 of the Amended and Restated Certificate of Incorporation of the Corporation (as

Consulting Services Agreement, effective as of February 4, 2023, by and between the Registrant and RDBio Consulting LLC.

Exhibit 10.2 CONSULTING SERVICES AGREEMENT This Consulting Services Agreement (this “Agreement”), effective as of February 4, 2023, (“Effective Date”) is between INVIVYD, Inc. a Delaware corporation having a place of business at 1601 Trapelo Road, Suite 178, Waltham, MA 02451, and its successors or assignees (“Invivyd” or the “Company”) and RDBio Consulting LLC, a Pennsylvania Limited Liability Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40703 INVIVYD, INC.

Non-Employee Director Compensation Policy (incorporated by reference to Exhibit 10.3 of the Registrant’s Quarterly Report on Form 10-Q (File No. 001-40703), filed with the Securities and Exchange Commission on May 11, 2023).

Exhibit 10.3 Invivyd, Inc. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Invivyd, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy for his or her Board service.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2023 Invivyd, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2023 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Invivyd Reports First Quarter 2023 Financial Results and Business Highlights Completed dosing of the Phase 1 clinical trial of VYD222, a broadly neutralizing monoclonal antibody (mAb) candidate being developed to protect immunocompromised people from

EX-99.1 Exhibit 99.1 Invivyd Reports First Quarter 2023 Financial Results and Business Highlights Completed dosing of the Phase 1 clinical trial of VYD222, a broadly neutralizing monoclonal antibody (mAb) candidate being developed to protect immunocompromised people from COVID-19 Initial data readouts from Phase 1 VYD222 clinical trial planned for Q2 with additional clinical readouts from the VYD2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 26, 2023 Invivyd, Inc. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 26, 2023 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of his

EX-99.1 Exhibit 99.1 Corporate Overview May 2023 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,” “should,” “expect,” “plan,”

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.3 of the Registrant’s Annual Report on Form 10-K (File No. 001-40703), filed with the Securities and Exchange Commission on March 23, 2023).

Exhibit 4.3 EXECUTION VERSION NEITHER THIS WARRANT NOR THE SECURITIES FOR WHICH THIS WARRANT IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 23, 2023 Invivyd, Inc. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 23, 2023 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Form of Indemnification Agreement with Executive Officers and Directors

Exhibit 10.4 INVIVYD, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is dated as of , 20, and is between Invivyd, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). RECITALS A. Indemnitee’s service to the Company substantially benefits the Company. B. Individuals are reluctant to serve as directors or officers of corporations or in certain other cap

Invivyd Reports Full Year 2022 Financial Results and Business Highlights Advancing VYD222 into clinical development based on in vitro data demonstrating neutralizing activity against multiple important variants of concern, including XBB.1.5 Anticipat

EX-99.1 Exhibit 99.1 Invivyd Reports Full Year 2022 Financial Results and Business Highlights Advancing VYD222 into clinical development based on in vitro data demonstrating neutralizing activity against multiple important variants of concern, including XBB.1.5 Anticipate near-term designation of an additional monoclonal antibody against SARS-CoV-2 with complementary binding properties to VYD222 f

Exhibit 4.2

Exhibit 4.2 DESCRIPTION OF INVIVYD, INC. COMMON STOCK The following description of the common stock of Invivyd, Inc., or the Company, and certain provisions of the Company’s amended and restated certificate of incorporation, or the Restated Certificate, and amended and restated bylaws, or the Bylaws, are summaries. These summaries are qualified in their entirety by reference to the provisions of t

Separation Agreement by and between the Registrant and Jane Pritchett Henderson, dated November 11, 2022.

Exhibit 10.23 SEPARATION AGREEMENT October 12, 2022, as modified on November 11, 2022 Jane Henderson [***] [***] Re: Separation Agreement Dear Jane: This letter sets forth the substance of the separation agreement (the “Agreement”) which Invivyd, Inc. (the “Company”) is offering to you to aid in your employment transition. 1. Separation. Your last day of work with the Company and your employment t

Clinical Master Services Agreement by between the Registrant and WuXi Biologics (Hong Kong) Limited, dated July 21, 2020 (incorporated by reference to Exhibit 10.17 of the Registrant’s Annual Report on Form 10-K (File No. 001-40703), filed with the Securities and Exchange Commission on March 23, 2023).

Exhibit 10.17 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***]”, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. MASTER SERVICES AGREEMENT This Master Services Agreement (this “Agreement”) is dated July 21, 2020 (the “Effective Date”) and is between Adagio Therapeutics, Inc. (“Client”), wi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40703 INVIVYD, INC. (

Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 of the Registrant’s Annual Report on Form 10-K (File No. 001-40703), filed with the Securities and Exchange Commission on March 23, 2023).

Exhibit 21.1 Invivyd, Inc. Subsidiaries 1. Invivyd Security Corporation 2. Invivyd Switzerland GmbH 3. Invivyd Netherlands B.V.

Work Order by and between the Registrant and Population Health Partners, L.P., dated November 15, 2022.

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***]”, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

Master Services Agreement by and between the Registrant and Population Health Partners, L.P., dated November 15, 2022.

EX-10 8 ivvd-ex1020.htm EX-10.20 Exhibit 10.20 MASTER SERVICES AGREEMENT THIS MASTER SERVICES AGREEMENT (this “Agreement”) is made as of November 15, 2022 (the “Effective Date”) by and between Invivyd, Inc., a Delaware corporation with a principal office at 1601 Trapelo Road, Suite 178, Waltham, MA 02451 (“Invivyd”), and Population Health Partners, L.P., a Delaware limited partnership, with a prin

Amendment Number One to the Collaboration Agreement by and between the Registrant and Adimab, LLC, November 18, 2022 (incorporated by reference to Exhibit 10.13 of the Registrant’s Annual Report on Form 10-K (File No. 001-40703), filed with the Securities and Exchange Commission on March 23, 2023).

Exhibit 10.13 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***]”, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NUMBER ONE TO THE COLLABORATION AGREEMENT This Amendment Number One (this “Amendment”), dated November 18, 2022 (the “Amendment One Effective Date”), amends the Collab

Amendment No. 1 to the Cell Line License Agreement by and between the Registrant and WuXi Biologics (Hong Kong) Limited, dated February 2, 2023 (incorporated by reference to Exhibit 10.16 of the Registrant’s Annual Report on Form 10-K (File No. 001-40703), filed with the Securities and Exchange Commission on March 23, 2023).

CONFIDENTIAL Exhibit 10.16 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***]”, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. CONFIDENTIAL AMENDMENT NO. 1 TO THE CELL LINE LICENSE AGREEMENT THIS AMENDMENT NO. 1 TO THE CELL LINE LICENSE AGREEMENT (this “Amendment”), effective as of February

INVIVYD OPTIMIZES DEVELOPMENT EFFICIENCY WITH ELECTION OF VYD222 FOR NEAR-TERM CLINICAL ADVANCEMENT TO ADDRESS URGENT UNMET NEED FOR COVID-19 MONOCLONAL ANTIBODIES Company seeks to utilize emerging global COVID-19 regulatory frameworks to accelerate

EX-99.1 Exhibit 99.1 INVIVYD OPTIMIZES DEVELOPMENT EFFICIENCY WITH ELECTION OF VYD222 FOR NEAR-TERM CLINICAL ADVANCEMENT TO ADDRESS URGENT UNMET NEED FOR COVID-19 MONOCLONAL ANTIBODIES Company seeks to utilize emerging global COVID-19 regulatory frameworks to accelerate development of VYD222 and its pipeline of other candidates VYD222 mAb candidate has demonstrated in vitro neutralizing activity a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 6, 2023 Invivyd, Inc. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 6, 2023 Invivyd, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I

FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-l

EX-99.2 3 d442726dex992.htm EX-99.2 Exhibit 99.2 TD Cowen 43rd Annual Health Care Conference March 6, 2023 FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words such as “may,” “wi

1 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward

EX-99.1 J.P. Morgan 41st Annual Healthcare Conference January 2023 Exhibit 99.1 1 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,” “should,” “expect,”

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 9, 2023 Invivyd, Inc. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 9, 2023 Invivyd, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 6, 2022 Invivyd, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Employment Agreement by and between the Registrant and Jeremy Gowler, dated September 17, 2022 (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K (File No. 001-40703), filed with the Securities and Exchange Commission on December 6, 2022).

Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made between Invivyd, Inc., a Delaware corporation (the ?Company?), and Jeremy Gowler (?Executive?), this 17th day of September 2022. WHEREAS, the Company desires for Executive to provide services to the Company, and wishes to provide Executive with certain compensation and benefits in return for such employment services,

INVIVYD APPOINTS JEREMY GOWLER AS CHIEF OPERATING AND COMMERCIAL OFFICER, PROMOTES PETE SCHMIDT, M.D., TO CHIEF MEDICAL OFFICER

Exhibit 99.1 INVIVYD APPOINTS JEREMY GOWLER AS CHIEF OPERATING AND COMMERCIAL OFFICER, PROMOTES PETE SCHMIDT, M.D., TO CHIEF MEDICAL OFFICER WALTHAM, MASS; December 06, 2022 ? Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced the appointment of Jeremy Gowler as chief operating and comme

INVIVYD ANNOUNCES PARTNERSHIP WITH POPULATION HEALTH PARTNERS TO ACCELERATE CLINICAL DEVELOPMENT IN INFECTIOUS DISEASES INCLUDING COVID-19 -Broad partnership will strengthen Invivyd’s development platform and organizational capabilities towards accel

EX-99.1 Exhibit 99.1 INVIVYD ANNOUNCES PARTNERSHIP WITH POPULATION HEALTH PARTNERS TO ACCELERATE CLINICAL DEVELOPMENT IN INFECTIOUS DISEASES INCLUDING COVID-19 -Broad partnership will strengthen Invivyd’s development platform and organizational capabilities towards acceleration of NVD200 clinical program and future engineered antibodies for COVID-19 and beyond- -Population Health Partners to integ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 15, 2022 Invivyd, Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 15, 2022 Invivyd, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number

2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.6 of the Registrant’s Quarterly Report on Form 10-Q (File No. 001-40703), filed with the Securities and Exchange Commission on November 10, 2022).

Exhibit 10.6 INVIVYD, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JULY 27, 2021 APPROVED BY THE STOCKHOLDERS: JULY 29, 2021 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purch

Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights Novel monoclonal antibody combination candidate (NVD200) on track to advance into clinical trials in Q1 2023 $419 million in cash, cash equivalents and marketable securities

Exhibit 99.1 Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights Novel monoclonal antibody combination candidate (NVD200) on track to advance into clinical trials in Q1 2023 $419 million in cash, cash equivalents and marketable securities expected to support operating runway into Q2 2024 Conference call scheduled for Thursday, November 10th at 4:30 p.m. ET Waltham, MA ? No

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 10, 2022 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40703 INVIVYD, INC.

2021 Equity Incentive Plan and Forms of Option Grant Notice and Agreement, Exercise Notice, Early Exercise Notice and Restricted Stock Award Notice (incorporated by reference to Exhibit 10.5 of the Registrant’s Quarterly Report on Form 10-Q (File No. 001-40703), filed with the Securities and Exchange Commission on November 10, 2022).

Exhibit 10.5 INVIVYD, INC. 2021 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JULY 27, 2021 APPROVED BY THE STOCKHOLDERS: JULY 29, 2021 1. GENERAL. (a) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; (ii) the Prior Plan?s Available Reserve

2020 Equity Incentive Plan and Forms of Stock Option Grant Notice, Stock Option Agreement, and Exercise Notice (incorporated by reference to Exhibit 10.4 of the Registrant’s Quarterly Report on Form 10-Q (File No. 001-40703), filed with the Securities and Exchange Commission on November 10, 2022).

Exhibit 10.4 INVIVYD, INC. 2020 EQUITY INCENTIVE PLAN ARTICLE I. PURPOSE. The purpose of the Plan is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing such persons with equity ownership opportunities and thereby better aligning the i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 20, 2022 Invivyd, Inc. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 20, 2022 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Num

INVIVYD ANNOUNCES THE APPOINTMENT OF CHRISTINE LINDENBOOM TO BOARD OF DIRECTORS

Exhibit 99.1 INVIVYD ANNOUNCES THE APPOINTMENT OF CHRISTINE LINDENBOOM TO BOARD OF DIRECTORS WALTHAM, MASS; October 24, 2022 ? Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced the appointment of Christine Lindenboom, senior vice president investor relations & corporate communications a

Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery

EX-99.1 Exhibit 99.1 Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery Platform WALTHAM, MASS; October 13, 2022 – Invivyd, (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced the appointment of Fred Driscoll as interim

Consulting Services Agreement, effective as of October 13, 2022, by and between Invivyd, Inc. and Fred Driscoll.

EX-10.2 Exhibit 10.2 CONSULTING SERVICES AGREEMENT THIS CONSULTING SERVICES AGREEMENT (this “Agreement”), effective as of October 13, 2022, is between INVIVYD, INC. a Delaware corporation having a place of business at 1601 Trapelo Road, Suite 178, Waltham, MA 02451, and its successors or assignees (“Invivyd” or the “Company”) and Fred Driscoll, having a place of business at [***] (“Consultant”). W

Form of Separation Agreement to be entered into between Invivyd, Inc. and Jane Pritchett Henderson.

EX-10.1 Exhibit 10.1 SEPARATION AGREEMENT October 12, 2022 Jane Henderson [***] [***] Re: Separation Agreement Dear Jane: This letter sets forth the substance of the separation agreement (the “Agreement”) which Invivyd, Inc. (the “Company”) is offering to you to aid in your employment transition. 1. Separation. Your last day of work with the Company and your employment termination date will be Nov

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 11, 2022 Invivyd, Inc. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 11, 2022 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Num

INVIVYD, INC. 1601 Trapelo Road, Suite 178 Waltham, MA 02451

INVIVYD, INC. 1601 Trapelo Road, Suite 178 Waltham, MA 02451 October 3, 2022 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Daniel Crawford Re: Invivyd, Inc. Registration Statement on Form S-3 Filed September 28, 2022 File No. 333-267643 Request for Acceleration of Effective Date Dear Mr. Cra

As filed with the Securities and Exchange Commission on September 28, 2022

Table of Contents As filed with the Securities and Exchange Commission on September 28, 2022 Registration No.

Form of Indenture (filed herewith).

Exhibit 4.4 INDENTURE DATED AS OF , 20 BETWEEN Invivyd, Inc. as Issuer, AND as Trustee Providing for Issuance of Debt Securities in Series TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01 Definitions 1 Section 1.02 Compliance Certificates and Opinions 6 Section 1.03 Form of Documents Delivered to Trustee 6 Section 1.04 Acts of Holders; Record

Delaware Certificate of Change of Registered Agent (incorporated by reference to Exhibit 3.3 of the Company's Registration Statement on Form S-3 (File No. 333-267643), filed with the Securities and Exchange Commission on September 28, 2022).

Exhibit 3.3 STATE OF DELAWARE CERTIFICATE OF CHANGE OF REGISTERED AGENT AND/OR REGISTERED OFFICE The corporation organized and existing under the General Corporation Law of the State of Delaware, hereby certifies as follows: 1. The name of the corporation is Invivyd, Inc. . 2. The Registered Office of the corporation in the State of Delaware is changed to Corporation Trust Center, 1209 Orange Stre

Filing Fee Table (filed herewith).

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee (

Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 of the Company’s Current Report on Form 8-K (File No. 001-40703), filed with the Securities and Exchange Commission on September 13, 2022).

Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF INVIVYD, INC. (A DELAWARE CORPORATION) September 13, 2022 INVIVYD, INC. AMENDED AND RESTATED BYLAWS ARTICLE I OFFICES Section 1. Registered Office. The registered office shall be established and maintained at the office of Incorporating Services, Ltd., 3500 S. Dupont Hwy, in the city of Dover, county of Kent, Delaware 19901, and said corporation, or other

Certificate of Amendment to the Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K (File No. 001-40703), filed with the Securities and Exchange Commission on September 13, 2022).

EXHIBIT 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ADAGIO THERAPEUTICS, INC. Adagio Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: FIRST: That the Board of Directors of the Corporation, by the unanimous written consent of its members, adopted resolutions

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 9, 2022 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Adagio Therapeutics Announces Corporate Name Change to Invivyd

Exhibit 99.1 Adagio Therapeutics Announces Corporate Name Change to Invivyd ? New name reflects Company focus on leveraging its integrated discovery platform to generate anti-viral antibodies that transcend the limits of naturally occurring immunity ? The Invivyd corporate mission is to provide antibody solutions that provide superior protection against viral diseases, starting with COVID-19 ? Com

This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words su

Investor Presentation September 2022 Transcending the limitations of the immune system Exhibit 99.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 12, 2022 Adagio Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commi

Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron Variants

Exhibit 99.2 Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron Variants - Integrated discovery platform is producing a stream of candidate antibodies demonstrating broad in vitro neutralization against past variants of concern (e.g., D614G, beta, delta) and Omicron sublineages BA.

ADGI / Adagio Therapeutics, Inc. / M28 Capital Management LP - ADAGIO THERAPEUTICS, INC. Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Adagio Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 00534A102 (CUSIP Number) M28 Capital Management LP 700 Canal Street, 2nd Floor Stamford, CT 06902 Eleazer Klein, Esq. Adriana Schwartz, Esq. Schulte Roth & Zabe

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 15, 2022 Adagio Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40703 Adagio Therapeutics, Inc.

Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights $475 Million in Cash and Cash Equivalents to Support Operating Runway into Second Quarter of 2024 Integrated Discovery Platform Identifies Multiple New Candidat

Exhibit 99.1 Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights $475 Million in Cash and Cash Equivalents to Support Operating Runway into Second Quarter of 2024 Integrated Discovery Platform Identifies Multiple New Candidates for COVID-19 Prevention and Treatment with Plans to Enter Clinical Trials in the First Quarter of 2023 Waltham, MA ? August 15, 2022 ?

ADGI / Adagio Therapeutics, Inc. / MITHRIL II LP - SC 13D/A Activist Investment

SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4) ADAGIO THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 00534A102 (CUSIP Number) Ajay Royan Mithril II LP c/o Mithril Capital Management 600 Congress Avenue, Suite 3100 Austin, TX 78701 (512) 717-3770

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 1, 2022 Adagio Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File

Employment Agreement by and between the Registrant and David Hering, dated July 5, 2022 (incorporated by reference to Exhibit 10.1 of the Company's Current Report on Form 8-K (File No. 001-40703), filed with the Securities and Exchange Commission on July 5, 2022).

EX-10.1 2 d304609dex101.htm EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between Adagio Therapeutics, Inc., a Delaware corporation (the “Company”), and David Hering (the “Executive”), this 5h day of July, 2022. This Agreement supersedes in its entirety that certain Amended and Restated Employment Agreement, dated August 5, 2021, as amended on February 2

Adagio Announces David Hering Named Permanent Chief Executive Officer and Director

Exhibit 99.2 Adagio Announces David Hering Named Permanent Chief Executive Officer and Director Waltham, MA ? July 5, 2022 ? Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases, announced today that industry and infectious disease veteran David Hering, wh

Adagio Announces Results of Annual Meeting of Stockholders and Evolution of the Board of Directors Marc Elia Named Chair of the Board of Directors

Exhibit 99.1 Adagio Announces Results of Annual Meeting of Stockholders and Evolution of the Board of Directors Marc Elia Named Chair of the Board of Directors Waltham, MA ? July 01, 2022 ? Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases, announced to

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 24, 2022 Adagio Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission Fil

ADGI / Adagio Therapeutics, Inc. / MITHRIL II LP - SC 13D/A Activist Investment

SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) ADAGIO THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 00534A102 (CUSIP Number) Ajay Royan Mithril II LP c/o Mithril Capital Management 600 Congress Avenue, Suite 3100 Austin, TX 78701 (512) 717-3770

ADGI / Adagio Therapeutics, Inc. / Adimab, LLC - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Adagio Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 00534A102 (CUSIP Number) Philip Chase 7 Lucent Drive Lebanon, NH 03766 (603) 643-7110 (Name, Address and Telephone Number of Pers

ADGI / Adagio Therapeutics, Inc. / Polaris Venture Partners V, L.P. - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) ADAGIO THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 00534A102 (CUSIP Number) Lauren Crockett Polaris Partners One Marina Park Drive, 10th Floor Boston, MA 02210 (781) 290-0770 (Name, Address and Telephone

ADGI / Adagio Therapeutics, Inc. / M28 Capital Management LP - ADAGIO THERAPEUTICS, INC. Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Adagio Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 00534A102 (CUSIP Number) M28 Capital Management LP 700 Canal Street, 2nd Floor Stamford, CT 06902 Eleazer Klein, Esq. Adriana Schwartz, Esq. Schulte Roth & Zabe

ADGI / Adagio Therapeutics, Inc. / Population Health Equity Partners III, L.P. - SCHEDULE 13D (AMENDMENT NO. 2) Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) ADAGIO THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 00534A102 (CUSIP Number) Christopher Cox Population Health Partners, L.P. 1200 Morris Turnpike, Suite 3005 Short Hills, NJ 07078 (212) 993-3113 (Name, Ad

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2022 ADAGIO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40703 83-1403134 (State or other jurisdiction of incorporation) (Commission

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 17, 2022 Adagio Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-40703 81-1403134 (State or Other Jurisdiction of Incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. )

DEFA14C 1 d371071ddefa14c.htm DEFA14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Inf

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. )

DEFC14C 1 d301673ddefc14c.htm DEFC14C Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)

PRELIMINARY INFORMATION STATEMENT – SUBJECT TO COMPLETION – DATED MAY 31, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange

PRER14C 1 d301673dprer14c.htm PRER14C Table of Contents PRELIMINARY INFORMATION STATEMENT – SUBJECT TO COMPLETION – DATED MAY 31, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. 1) Check the appropriate box: ☒ Preliminary Information Statement

* * * * *

Lawrence S. Elbaum [email protected] Tel +1.212.237.0084 Fax +1.917.849.5379 May 31, 2022 VIA ELECTRONIC MAIL AND EDGAR FILING Christina Chalk, Esq. Senior Special Counsel Office of Mergers and Acquisitions Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-3561 Re: Adagio Therapeutics, Inc. PREC14A filed May 19, 2022 SEC File